SELLAS Life Sciences Group (SLS) Price & Analysis

Compare

1,068 Followers

SLS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.77 - $2.27

Previous CloseN/A

Volume1.43M

Average Volume (3M)2.26M

Market Cap

$191.64M

Enterprise Value$191.18M

Total Cash (Recent Filing)$25.40M

Total Debt (Recent Filing)$737.00K

Price to Earnings (P/E)―

Beta1.10

Next Earnings

Nov 12, 2025

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding105,297,470

10 Day Avg. Volume2,052,534

30 Day Avg. Volume2,259,536

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.26

Forecast

1Y Price Target

$7.00

Price Target Upside264.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressPositive interim analysis from the P3 REGAL study evaluating GPS in AML with a recommendation to continue without modification.

Efficacy And SafetySLS009 in combination with venetoclax + azacitidine in relapsed/refractory AML exceeded its prespecified 20% ORR target with a 33% ORR across all evaluable patients.

Regulatory AdvancementSellas has FDA guidance to move the triplet now to 1L AML, which represents a significant positive for Sellas as it progresses this program.

Bears Say

Market PressureToday's share weakness is viewed as an opportunity ahead of the top-line P3 data.

Stock PerformanceSLS shares are down as much as 26%, possibly due to a slight run-up ahead of the data and some profit taking, as well as continued pressure in the biotech sector.

SELLAS Life Sciences Group News

Unusually active option classes on open August 21st

Unusual total active option classes on open include: Dayforce Inc (DAY), Crexendo Inc (EXE), Wal-Mart (WMT), iShares MSCI...

7d ago

ABT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Gorilla Technology Group Inc...

8d ago

SLS

VOR

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

“We continue to make significant progress in advancing our AML-focused pipeline, as demonstrated by the positive Phase 2...

16d ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sequans (SQNS) 85.88% +1.67,...

21d ago

FAZ

Sellas Life announces IDMC completed pre-specified analysis of Phase 3 REGAL

SELLAS Life Sciences (SLS) announced that the Independent Data Monitoring Committee, IDMC, has completed a pre-specified analysis of...

21d ago

SLS

Optimistic Buy Rating for SELLAS Life Sciences Group Driven by Promising Trial Results and Financial Stability

SELLAS Life Sciences Group, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason...

14d ago

SLS

Sellas Life Sciences Reports Q2 2025 Financial Results

Sellas Life Sciences Group ( ($SLS) ) has released its Q2 earnings. Here is a breakdown of the...

16d ago

SLS

SLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Sellas Life Sciences Group (SLS) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall...

24d ago

SLS

Sellas Life Sciences price target raised to $7 from $4 at Maxim

Maxim raised the firm’s price target on Sellas Life Sciences (SLS) to $7 from $4 and keeps a...

1M ago

SLS

Sellas Life Sciences meets all primary endpoints in Phase 2 trial of SLS009

SELLAS Life Sciences (SLS) Group announced that is has met all primary endpoints in its Phase 2 trial...

1M ago

SLS

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

SELLAS Life Sciences (SLS) announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board. Dr....

2M ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ocugen (OCGN) 233.66% +35.18,...

2M ago

JBS

RKT

Sellas Life Sciences to be added to Russell 3000, Russell 2000 indexes

SELLAS Life Sciences (SLS) announced that the Company will be added to the Russell 3000 and Russell 2000...

2M ago

SLS

SELLAS Life Sciences Holds Annual Stockholders Meeting

SELLAS Life Sciences Group ( ($SLS) ) has issued an announcement. On June 17, 2025, SELLAS Life Sciences...

2M ago

SLS

SLS FAQ

What was SELLAS Life Sciences Group’s price range in the past 12 months?

SELLAS Life Sciences Group lowest stock price was $0.77 and its highest was $2.27 in the past 12 months.

What is SELLAS Life Sciences Group’s market cap?

SELLAS Life Sciences Group’s market cap is $191.64M.

When is SELLAS Life Sciences Group’s upcoming earnings report date?

SELLAS Life Sciences Group’s upcoming earnings report date is Nov 12, 2025 which is in 76 days.

How were SELLAS Life Sciences Group’s earnings last quarter?

SELLAS Life Sciences Group released its earnings results on Aug 12, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.077 by $0.007.

Is SELLAS Life Sciences Group overvalued?

According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SELLAS Life Sciences Group pay dividends?

SELLAS Life Sciences Group does not currently pay dividends.

What is SELLAS Life Sciences Group’s EPS estimate?

SELLAS Life Sciences Group’s EPS estimate is -0.08.

How many shares outstanding does SELLAS Life Sciences Group have?

SELLAS Life Sciences Group has 105,297,470 shares outstanding.

What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?

SELLAS Life Sciences Group reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.077. Following the earnings report the stock price went down -3.727%.

Which hedge fund is a major shareholder of SELLAS Life Sciences Group?

Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at 0.

SELLAS Life Sciences Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

-180.71%

Trailing 12-Months

Asset Growth

113.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SELLAS Life Sciences Group (SLS) Earnings & Revenues

Historic Earnings Reports

SLS Stock 12 Month Forecast

Average Price Target

$7.00

▲(264.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.0707692307692307,2.4815384615384612,2.8923076923076922,3.3030769230769232,3.713846153846154,4.124615384615384,4.535384615384616,4.946153846153846,5.356923076923077,5.7676923076923075,6.178461538461539,6.5892307692307694,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.0707692307692307,2.4815384615384612,2.8923076923076922,3.3030769230769232,3.713846153846154,4.124615384615384,4.535384615384616,4.946153846153846,5.356923076923077,5.7676923076923075,6.178461538461539,6.5892307692307694,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.0707692307692307,2.4815384615384612,2.8923076923076922,3.3030769230769232,3.713846153846154,4.124615384615384,4.535384615384616,4.946153846153846,5.356923076923077,5.7676923076923075,6.178461538461539,6.5892307692307694,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >